Navigation Links
AMERIGROUP Corporation to Discuss Third Quarter Earnings on October 25
Date:10/10/2007

VIRGINIA BEACH, Va., Oct. 10 /PRNewswire-FirstCall/ -- AMERIGROUP Corporation (NYSE: AGP) today announced that it will report its earnings for the third quarter ended September 30, 2007, after the market closes on Wednesday, October 24, 2007. At 9:30 a.m. Eastern Time on Thursday, October 25, 2007, AMERIGROUP's management will host a conference call and webcast to discuss earnings and other information.

To listen to the call, dial 866-260-3161 (domestic) or 706-679-7245 (international) and provide passcode 18786503 approximately ten minutes prior to the start time of the call. The conference call will also be available through the investors' page of the Company's Web site, http://www.amerigroupcorp.com , or through http://www.earnings.com .

A telephonic replay of this call will be available beginning on Thursday, October 25 at 1:00 p.m. Eastern Time through Thursday, November 1. This replay may be accessed by dialing 800-642-1687 (domestic) or 706-645-9291 (international) and providing passcode 18786503. A replay of the webcast will also be available at the sites listed above for 30 days, beginning approximately two hours after its conclusion.

AMERIGROUP Corporation, headquartered in Virginia Beach, Virginia, improves healthcare access and quality for the financially vulnerable, seniors and people with disabilities by developing innovative managed health services for the public sector. Through its subsidiaries, AMERIGROUP Corporation serves more than 1.5 million people in the District of Columbia, Florida, Georgia, Maryland, New Jersey, New York, Ohio, Tennessee, Texas and Virginia. For more i
'/>"/>

SOURCE AMERIGROUP Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
2. Who Board To Discuss Asian Tsunami Related Health Issues
3. Physicians To Discuss Ways To Save Premature Babies From RSV
4. Survey finds that discussion with family very crucial in organ donation decision
5. India And China Discuss Import Of Encephalitis Vaccine
6. North-Eastern Leaders Of India Meet To Discuss HIV Problems
7. US Officials To Discuss Effectiveness Of Plan To Face Bird Flu Threat
8. Chinese Health Officials To Discuss Preparation Of Bird Flu
9. Autism: Symposium to Discuss Myths and Misconceptions
10. Southern States Health Ministers To Discuss Ways To Stop Chikungunya
11. China India to Discuss Bird Flu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...nts were checked, only 39% met treatment goals , ...dangers of high blood pressure are well-known, but...e screening in doctor,s offices and a low percenta... blood pressure goals after diagnosis. , The St...hed in the May issue of Hypertension, found that...
(Date:5/12/2008)...May 12, 08:30 a.m. EDT at ...ay 12 /PRNewswire-FirstCall/ -- Isis,Pharmaceutica...ncial results,for the quarter ended March 31, 2008...a net operating loss (NOL) of $5.1 million, exclud... compared to a pro forma NOL,of $18.5 million in t...
(Date:5/12/2008)...all/ - Innolife Pharma, Inc.,(Other OTC:INNP.PK - ...ht,months regarding the formation of a joint ventu...negotiations where final written terms have been,s... Company,s very first,product acquisition. It shou... over this extended period due to the successful, ...
(Date:5/12/2008)...s of over $25 million, OWINGS MILLS, Md., May 12 ...ED ) announced today first quarter financial resul...ial highlights included:, -- First quarter revenu...75.8% vs. 74.8%, -- The direct sales segment of T...of 63% year-over-year;, -- Medifast Weight Contro...
Breaking Medicine News(10 mins):Health News:High Blood Pressure Still Slipping Past Doctors 2Health News:High Blood Pressure Still Slipping Past Doctors 3Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 2Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 3Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 4Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 5Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 6Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 7Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 8Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 9Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 10Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 11Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 12Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 13Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 14Health News:Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture 2Health News:Medifast Announces First Quarter 2008 Financial Results 2Health News:Medifast Announces First Quarter 2008 Financial Results 3Health News:Medifast Announces First Quarter 2008 Financial Results 4Health News:Medifast Announces First Quarter 2008 Financial Results 5Health News:Medifast Announces First Quarter 2008 Financial Results 6Health News:Medifast Announces First Quarter 2008 Financial Results 7Health News:Medifast Announces First Quarter 2008 Financial Results 8
...pecies with unpaired electrons have been implicate...ancer. The scientific community has been trying ha... free radicals by supplementation with anti-oxidan...radicals. // Anti-oxidants are abundant in fruits ...
... been a quest regarding the treatment of AIDS/HIV ...e the initiation of a global research, AIDS still ...imately five percent of patients with HIV, or huma...op AIDS, or do so very slowly.// Past research su...
...h team led by Professor Claudio Soto from the Univ...rion’ proteins behind such diseases in the blood o... the proteins that cause Mad Cow disease, raising ... form of the condition, Creutzfeldt-Jackobson dise...
... are often the ones who make fewer visits to the d...appens in spite of the fact that smoking puts them...s.// The finding holds true regardless of age, ge...cioeconomic status, location and insurance coverag...
Other Medicine News:Health News:Study holds promise for new way to fight HIV 2Health News:Blood Test To Detect Creutzfeldt-Jakob Disease/Mad Cow Disease 2
(Date:5/8/2008)...Treatment Provides "Blueprint" to Produce Therapeu...Ill., May 8 /PRNewswire-USNewswire/ -- Using gene,...ghting proteins through,skin flaps placed on cance... tumor volume, according to a study in the May iss...fficial medical journal of the American,Society of...
(Date:5/8/2008)...ther Data Presentations to Focus on Use of Pro-Hea...ot Tolerate Dual-Antiplatelet Therapy, HONG KONG,... from both,a randomized pilot study and the real-w...eered R stent, the world,s first pro-healing stent...roPCR 2008 in Barcelona, Spain., The symposium, t...
(Date:5/8/2008)...tch Formulation May Provide New Option for Clinici...e When Using an Oral NSAID, TAMPA, Fla., May 8 /P...),a leading global specialty pharmaceutical compa...ed this week at the American Pain Society annual,m...positive pharmacokinetic,profile of Alpharma Pharm...
(Date:5/7/2008)... Study to Evaluate Preferred Induction Dosi... -- Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ...icals, a,division of Wyeth (NYSE: WYE ), has comm... trial of TRU-015 in patients with rheumatoid arth...harmaceuticals is developing,TRU-015, SBI-087 and ...
Breaking Medicine Technology:Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 3Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 4AlphaRx Officers and Directors To Exercise Options Warrants and Retain Shares 8896 1AlphaRx Officers and Directors To Exercise Options Warrants and Retain Shares 8896 2Boston Scientific Announces CE Mark Approval for Next Generation Cardiac Resynchronization Therapy Defibrillator 8892 1Boston Scientific Announces CE Mark Approval for Next Generation Cardiac Resynchronization Therapy Defibrillator 8892 2Boston Scientific Announces CE Mark Approval for Next Generation Cardiac Resynchronization Therapy Defibrillator 8892 3Caraco Pharmaceutical Laboratories Ltd Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets 28R 29 and Zyrtec Hives Relie 8888 1Caraco Pharmaceutical Laboratories Ltd Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets 28R 29 and Zyrtec Hives Relie 8888 2 Diabetes Group Backs Low Carb Diets 8887 1 Diabetes Group Backs Low Carb Diets 8887 2
...ggregate Benefit over Placebo Larger at One Year t... June 11, 2007,/PRNewswire-FirstCall/ -- Medivatio...on over placebo in its double-blind,placebo-contr...,s,disease were statistically significant on all f...every endpoint studied, the benefits,of Dimebon ov...
...W HAVEN, Conn., June 11, 2007 /PRNewswire-FirstCal... presented clinical data in,a poster session at th...tion (EHA) Meeting in Vienna, Austria on its lead ...ingle agent in a,multi-center international Phase ...with acute myelogenous leukemia (AML) or high-risk...
Other Medicine Technology:Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 2Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 3Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 4Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 5Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 6Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial,of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable,Cytogenetics at EHA Meeting 2Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial,of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable,Cytogenetics at EHA Meeting 3Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial,of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable,Cytogenetics at EHA Meeting 4
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem.
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem.
Micro Seal Acetabular Liner
Longevity Crosslinked Polyethylene Liners
Medicine Products: